Shares of Roche Holding AG (OTCMKTS:RHHBY - Get Free Report) have received an average recommendation of "Moderate Buy" from the six ratings firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, one has given a hold rating, one has issued a buy rating and two have issued a strong buy rating on the company.
RHHBY has been the subject of a number of research analyst reports. Morgan Stanley initiated coverage on Roche in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. Sanford C. Bernstein upgraded Roche to a "strong-buy" rating in a research note on Thursday, January 30th. Finally, UBS Group upgraded shares of Roche from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th.
Get Our Latest Analysis on Roche
Institutional Investors Weigh In On Roche
Hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in Roche by 6,463.8% during the 1st quarter. GAMMA Investing LLC now owns 528,778 shares of the company's stock worth $21,759,000 after acquiring an additional 520,722 shares during the period. Bard Financial Services Inc. boosted its position in shares of Roche by 156.8% in the 3rd quarter. Bard Financial Services Inc. now owns 80,500 shares of the company's stock worth $3,216,000 after purchasing an additional 49,150 shares during the last quarter. Boston Common Asset Management LLC grew its stake in shares of Roche by 10.0% during the first quarter. Boston Common Asset Management LLC now owns 325,732 shares of the company's stock worth $13,369,000 after purchasing an additional 29,522 shares during the period. Minot DeBlois Advisors LLC bought a new stake in Roche in the fourth quarter valued at about $752,000. Finally, SVB Wealth LLC acquired a new position in Roche in the fourth quarter valued at about $555,000.
Roche Price Performance
OTCMKTS:RHHBY traded down $1.65 during midday trading on Thursday, reaching $36.00. The stock had a trading volume of 3,134,478 shares, compared to its average volume of 3,243,924. Roche has a 1-year low of $29.20 and a 1-year high of $44.31. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.97 and a current ratio of 1.26. The firm's fifty day simple moving average is $41.34 and its 200-day simple moving average is $38.69.
About Roche
(
Get Free ReportRoche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Featured Articles

Before you consider Roche, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.
While Roche currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.